Gilead Sciences Inc. has announced new clinical data that will be presented at the European Society for Medical Oncology (ESMO) 2025 Congress taking place from October 17 to 21. The company will present late-breaking results from the Phase 3 ASCENT-03 study evaluating Trodelvy® (sacituzumab govitecan-hziy) as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. Gilead previously reported that the ASCENT-03 study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy in this patient population. Additionally, Gilead and Arcus Biosciences will present overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study. This study evaluates the combination of the anti-TIGIT antibody domvanalimab, anti-PD-1 antibody zimberelimab, and chemotherapy in patients with advanced gastric or esophageal cancer. In this study arm, the median overall survival was 26.7 months, with 50 percent of patients living more than two years. Further results, including analyses of quality of life from the ASCENT-04/KEYNOTE-D19 study, will also be presented at the upcoming congress.